Following its strategic review, and off the back of two critical clinical trial updates - the opening of Cynata’s acute Graft-versus-host disease trial for enrolment and the approval of its Phase 1 clinical trial in kidney transplant patients - CEO Dr Kilian Kelly sat down with Kalkine Media to discuss the milestones.